Related Experiment Video
Updated: Jul 15, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics
Yuda Zhang1,2, Fanxu Zeng2, Shixuan Peng1,3
1Department of Oncology, Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Introduction:
KRAS is the most frequently mutated oncogene in cancer and encodes a key signaling protein in tumors. Due to its high affinity for GTP and the lack of a large binding pocket that allosteric inhibitors can occupy, KRAS has long been considered 'non-druggable.' Finding effective treatment measures for patients with KRAS mutations is our top priority.
Areas Covered:
In this article, we will provide an overview of the KRAS pathway and review the current state of therapeutic strategies for targeting oncogenic KRAS, as well as their potential to improve outcomes in patients with KRAS-mutant malignancies. We will also discuss the development of these strategies and gave an outlook on prospects.
Expert Opinion:
KRAS mutations have posed a significant challenge in the treatment of advanced non-small cell lung cancer (NSCLC) over the past few decades. However, the emergence of immunotherapy and KRAS inhibitors, such as Sotorasib (AMG 510) and Adagrasib (MRTX849), has marked a new era in cancer therapy. As more research and clinical trials continue, we anticipate the development of more effective treatment strategies and better options for lung cancer patients.
Insights
Targeting KRAS mutations, historically challenging in cancer, is advancing with new inhibitors. These therapies offer improved outcomes for patients with KRAS-mutant cancers, particularly non-small cell lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- KRAS is a frequently mutated oncogene crucial in tumor signaling.
- Its structure historically made KRAS proteins 'non-druggable' for cancer therapies.
- Effective treatments for KRAS mutations are a priority in oncology.
Purpose of the Study:
- To provide an overview of the KRAS pathway.
- To review current therapeutic strategies targeting oncogenic KRAS.
- To discuss the development and future prospects of KRAS-targeted therapies.
Main Methods:
- Review of existing literature on KRAS pathway and targeted therapies.
- Analysis of clinical trial data for KRAS inhibitors.
- Discussion of emerging treatment strategies and their clinical implications.
Main Results:
- KRAS mutations present a significant challenge in advanced non-small cell lung cancer (NSCLC).
- Emerging KRAS inhibitors like Sotorasib and Adagrasib represent a new era in cancer therapy.
- Immunotherapy combined with KRAS inhibitors shows promise for improved patient outcomes.
Conclusions:
- Targeting KRAS mutations is evolving with novel therapeutic strategies.
- KRAS inhibitors are improving treatment options for KRAS-mutant malignancies, especially NSCLC.
- Continued research and clinical trials are expected to yield more effective treatments.
